Otero Jose Manuel 4

What Happened
Jose Manuel Otero, Chief Operating Officer of Lexeo Therapeutics (LXEO), received an award of 12,060 restricted stock units (RSUs) on 2026-06-29 (reported as acquired at $0.00). On 2026-07-01 he disposed of 4,666 shares in an open-market sale at a weighted-average price of $4.48 per share for total proceeds of $20,904. The filing indicates the sale was executed to cover tax obligations related to the RSU release.

Key Details

• Transactions reported: Award (A) — 12,060 RSUs on 2026-06-29; Sale (S) — 4,666 shares on 2026-07-01.
• Sale price: weighted average $4.48; individual trades ranged $4.35–$4.73 (footnote F2).
• Purpose of sale: tax withholding on RSU release (footnote F1).
• Holdings after transaction: the filing does not list total common shares beneficially owned; it notes inclusion of 100,621 RSUs (footnote F3).
• Timeliness: Form 4 filed 2026-07-01 (same day as sale) — appears timely.

Context
RSUs are a contingent right to receive shares in the future; the award was reported at $0 because it is an equity grant rather than a cash purchase. The sale here was a routine "sell-to-cover" for taxes and should be viewed as fulfilling withholding obligations rather than a clear signal of the insider's market view.